Bariatric Surgery Candidate Clinical Trial
Official title:
Evaluation of Body Composition and Metabolism Following Bariatric Surgery, Effects of a Protein Supplement: A Feasibility Study
NCT number | NCT02951663 |
Other study ID # | 16-0529 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2016 |
Est. completion date | February 2019 |
Verified date | March 2019 |
Source | University of North Carolina, Chapel Hill |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Purpose: To evaluate adherence, tolerability, and total protein intake in bariatric surgery
patients provided with ready-to-drink protein supplements, and to evaluate the effects of
supplementation on body composition, metabolism, and health outcomes.
Participants: Patients scheduled to under go bariatric surgery aged 18-70 years old.
Participants will be included if they agree to comply with the study protocol, are free of
medical conditions that may contraindicate participation, and do not plan to become pregnant
during the study.
Procedures (methods): Participants will complete five laboratory visits for the current study
(pre-screening (visit 1), baseline testing (visit 2), and return visits at 3 weeks (visit 3),
12 weeks (visit 4), and 24 weeks (visit 5) post-surgery). The treatment group will be given a
12 week supply of a high protein, low-carbohydrate, low-fat supplement to be taken once daily
during days 3-7 post-surgery, and twice daily weeks 2-12. The treatment group will follow
standard of care recommendations put forth by the physician-nutritionist team, but using the
provided protein supplement to meet recommendations. The control group will be asked to
follow the standard of care recommendations from the physician-nutritionist team.
The primary study endpoints will be adherence, tolerability, and total protein intake in
bariatric surgery patients provided with a 12-week supply of ready-to-drink protein
supplements. Secondary outcomes will evaluate the effect of a protein supplement on body
composition (lean mass, fat mass, percent body fat, visceral fat, muscle thickness), resting
metabolic rate, clinical and endocrine blood values, functional fitness, and responses to
questionnaires evaluating mood, satiety, functional independence, and health related quality
of life.
Status | Completed |
Enrollment | 48 |
Est. completion date | February 2019 |
Est. primary completion date | February 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Participant is scheduled for weight loss surgery - Participant agrees to abstain from extraneous supplementation with creatine, ß-hydroxy ß-methylbutyrate, carnosine, beta-alanine, taurine, or any other supplement or prescription drug that may significantly influence body composition or metabolic rate - Participant has provided written and dated informed consent to participate in the study - Participant is willing and able to comply with the protocol - Participant agrees to abstain from using caffeine, tobacco, and alcohol for at least 24 hours before testing days - Participant agrees to abstain from exercise 24 hours prior to each testing visit - Participant is not currently pregnant and does not desire to become pregnant in the next six months Exclusion Criteria: - Physicians on the research team believe that a pre-existing condition may influence participant safety or study outcomes, including previously diagnosed cardiovascular, metabolic, renal, hepatic, or musculoskeletal disorders - Participant is using, or has used one of the following dietary supplements within 8 weeks prior to enrollment: creatine, ß-hydroxy ß-methylbutyrate, carnosine, beta-alanine, taurine, or any other supplement or prescription drug that may significantly influence body composition or metabolic rate - Participant is in, or has participated in another clinical trial within 4 weeks prior to enrollment - Participant is pregnant or plans on becoming pregnant - Participant has a known allergy or sensitivity to any ingredient in the test product (determined from health history questionnaire) |
Country | Name | City | State |
---|---|---|---|
United States | Exercise & Sport Science and GI Surgery UNC Hospitals | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients reporting gastrointestinal effects during use of supplementation | Tracked using a custom survey | 12 weeks | |
Primary | Number of shakes consumed out of the total number of shakes provided | 12 weeks | ||
Secondary | Body fat | measured using ultrasound | 12 weeks | |
Secondary | Lean body mass | measured using ultrasound | 12 weeks | |
Secondary | Metabolism (resting metabolic rate) | 12 weeks | ||
Secondary | Functional fitness (sit to stand test) | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Active, not recruiting |
NCT04583683 -
Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities
|
N/A | |
Completed |
NCT04099654 -
The Effect of Core Stabilization Exercise Program in Obese Subjects Awaiting Bariatric Surgery
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT03638843 -
Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy - Part 2
|
N/A | |
Withdrawn |
NCT05845359 -
Intraoperative Methadone for Postoperative Pain Control
|
Phase 4 | |
Not yet recruiting |
NCT04343040 -
Perioperative Evaluation of Glucose Profile Using Continuous Glucose Monitoring System in Glucose Intolerant Patients
|
N/A | |
Withdrawn |
NCT03095404 -
Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery
|
Early Phase 1 | |
Recruiting |
NCT03100292 -
Korean OBEsity Surgical Treatment Study
|
N/A | |
Active, not recruiting |
NCT04357119 -
Common Limb Length in One-anastomosis Gastric Bypass
|
N/A | |
Completed |
NCT04883268 -
Focusing on Body Functionality After Bariatric Surgery
|
N/A | |
Completed |
NCT03210207 -
Gastric Plication in Mexican Patients
|
N/A | |
Completed |
NCT02300168 -
Neuromuscular Blockade: Outcome and Recovery for Laparoscopic Bariatric Surgery
|
N/A | |
Unknown status |
NCT01264120 -
The Impact of a Bariatric Rehabilitation Service on Patient Outcomes
|
N/A | |
Recruiting |
NCT03972319 -
Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study
|
Early Phase 1 | |
Terminated |
NCT04626232 -
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
|
N/A | |
Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|
||
Completed |
NCT04219852 -
Contraception and Bariatric Surgery: Evaluation of Contraception and Contraceptive Knowledge of Women Undergoing Bariatric Surgery at the University Hospital of Reims
|
||
Recruiting |
NCT05570474 -
Effect of Protein Supplementation on Fat Free Mass Preservation After Bariatric Surgery
|
N/A |